Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 1.54 HKD -5.52% Market Closed
Market Cap: 1.2B HKD
Have any thoughts about
Jacobio Pharmaceuticals Group Co Ltd?
Write Note

Jacobio Pharmaceuticals Group Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jacobio Pharmaceuticals Group Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Cash from Operating Activities
-ÂĄ364.2m
CAGR 3-Years
N/A
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ7.8B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash from Operating Activities
ÂĄ796.9m
CAGR 3-Years
-13%
CAGR 5-Years
9%
CAGR 10-Years
13%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
ÂĄ6.5B
CAGR 3-Years
-12%
CAGR 5-Years
54%
CAGR 10-Years
43%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Operating Activities
ÂĄ2B
CAGR 3-Years
66%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Jacobio Pharmaceuticals Group Co Ltd
Glance View

Market Cap
1.2B HKD
Industry
Biotechnology

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Intrinsic Value
0.92 HKD
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Jacobio Pharmaceuticals Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-364.2m CNY

Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Cash from Operating Activities amounts to -364.2m CNY.

What is Jacobio Pharmaceuticals Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-35%

Over the last year, the Cash from Operating Activities growth was -25%.

Back to Top